Analysts Set Expectations for CLDX FY2026 Earnings

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Stock analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Celldex Therapeutics in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska anticipates that the biopharmaceutical company will post earnings per share of ($4.68) for the year. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.48) per share.

A number of other research analysts have also commented on the stock. Morgan Stanley dropped their price objective on shares of Celldex Therapeutics from $46.00 to $43.00 and set an “overweight” rating on the stock in a research note on Friday, May 9th. UBS Group dropped their price objective on shares of Celldex Therapeutics from $44.00 to $38.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. Canaccord Genuity Group initiated coverage on shares of Celldex Therapeutics in a research note on Monday, April 28th. They issued a “buy” rating and a $64.00 price objective on the stock. HC Wainwright restated a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research note on Tuesday, May 6th. Finally, The Goldman Sachs Group dropped their price target on shares of Celldex Therapeutics from $36.00 to $31.00 and set a “neutral” rating on the stock in a research note on Friday, May 9th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $53.90.

Celldex Therapeutics Stock Performance

NASDAQ CLDX opened at $20.92 on Tuesday. The firm has a market cap of $1.39 billion, a PE ratio of -8.14 and a beta of 1.33. Celldex Therapeutics has a one year low of $14.40 and a one year high of $47.00. The firm’s fifty day moving average is $19.13 and its two-hundred day moving average is $21.90.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). The business had revenue of $0.70 million during the quarter, compared to analyst estimates of $1.08 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Rhumbline Advisers boosted its holdings in Celldex Therapeutics by 6.9% during the first quarter. Rhumbline Advisers now owns 98,266 shares of the biopharmaceutical company’s stock worth $1,784,000 after buying an additional 6,327 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Celldex Therapeutics by 12.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 131,296 shares of the biopharmaceutical company’s stock worth $2,383,000 after buying an additional 14,979 shares in the last quarter. Millennium Management LLC boosted its holdings in Celldex Therapeutics by 327.3% during the first quarter. Millennium Management LLC now owns 399,932 shares of the biopharmaceutical company’s stock worth $7,259,000 after buying an additional 306,330 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Celldex Therapeutics by 1.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock worth $798,000 after buying an additional 680 shares in the last quarter. Finally, ADAR1 Capital Management LLC purchased a new stake in Celldex Therapeutics during the first quarter worth about $265,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.